DashboardWarning LettersWarning Letter Details

Jabil Inc. Warning Letter Details

Warning Letter
View Letter

Jabil Inc.

Recipient Title Chief Executive Officer and Director, 10800 Roosevelt Blvd. N. St. Petersburg , FL 33716 United States, (b)(4)
Issue DateAugust 27, 2026
FEI Number3006503102
Violations4
CountryUnited States
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open

Subject

CGMP/Finished Pharmaceuticals/Adulterated

Jabil Inc. FDA Warning Letter, August 27, 2026